SPTX Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

19.900

Open

19.220

VWAP

18.68

Vol

157.91K

Mkt Cap

975.86M

Low

17.920

Amount

2.95M

EV/EBITDA(TTM)

Total Shares

53.53M

1.18B

EV/OCF(TTM)

P/S(TTM)

Seaport Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Its product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder. It is also advancing Glyph2BLS (SPT-348 or Glyph 2-bromo-LSD), a novel, Glyphed oral prodrug of the non-hallucinogenic LSD analog 2-bromo-LSD, in preclinical studies for depressive disorders. GlyphAllo is designed to overcome the bioavailability limitations of allopregnanolone and be durable in MDD.

Events Timeline

(ET)

2026-05-26

11:10:00

SpaceX Files for IPO Aiming to Raise $80 Billion

News

5.0

06-24NASDAQ.COM

Powerlaw CEO Dinsdale Buys $246K in Shares Amid Market Opportunities

9.5

06-09NASDAQ.COM

Seaport Therapeutics Reports Wider Net Loss in Q1 2026

9.0

06-09Newsfilter

Seaport Therapeutics Reports Positive Clinical Data for GlyphAgo

9.5

06-08seekingalpha

Seaport Therapeutics Reports Q1 Loss and IPO Success

8.5

06-08Newsfilter

Seaport Therapeutics Raises $260 Million in Successful IPO

9.0

06-08Yahoo Finance

GlyphAgo Repeat Dosing Shows Favorable Safety Profile

0 Analyst Rating

Wall Street analysts forecast SPTX stock price to rise

0 Buy

0 Hold

0 Sell

Current: 0.000

Low

Averages

High

Current: 0.000

Low

Averages

High

Wolfe Research

Rudy Li

Peer Perform

initiated

AI Analysis

2026-07-07

New

Reason

Wolfe Research

Rudy Li

Price Target

AI Analysis

2026-07-07

New

initiated

Peer Perform

Reason

Wolfe Research analyst Rudy Li initiated coverage of Seaport Therapeutics with a Peer Perform rating and no price target. We the firm likes the company's Glyph platform, it expects mixed data from the Phase 2b BUOY-1 study and calls lead asset SPT-300 "a risky bet" in major depressive disorder.

Goldman Sachs

Salveen

initiated

2026-05-26

Reason

Goldman Sachs

Salveen

Price Target

2026-05-26

initiated

Reason

Goldman Sachs analyst Salveen initiated coverage of Seaport Therapeutics with an Early-Stage Biotech rating and no price target. The company is developing oral small molecule therapies in neuropsychiatric disorders, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SPTX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Seaport Therapeutics Inc (SPTX.O) is 0.00, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess Seaport Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

Current PE

0.00

Overvalued PE

Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

Current PS

0.00

Overvalued PS

Undervalued PS

Financials

AI Analysis

Annual

Quarterly

Whales Holding SPTX

Trading Trends

People Also Watch

Frequently Asked Questions

What is Seaport Therapeutics Inc (SPTX) stock price today?

The current price of SPTX is 18.23 USD — it has decreased -5.89

What is Seaport Therapeutics Inc (SPTX)'s business?

What is the price predicton of SPTX Stock?

Wall Street analysts forecast SPTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPTX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.